Abstract:7010 Background: Genetic polymorphic variants (SNPs) of DNA- and histone-modifying genes, in particular O6- methylguanine DNA-methyltransferase (MGMT), have been implicated in increased risk for development of lung cancer. Methods: 165 SNPs in these genes were genotyped in 461 stage 1 and 2 non-small cell lung cancer (NSCLC) patients treated with surgery (N=337) or surgery and chemotherapy (N=124) and analyzed for association with recurrence and survival. Median survival times and recurrence rates were 89.1 months and 27.5 % (93/337) for surgery and >133.6 months and 29% (36/124) for surgery and chemotherapy, respectively. Results: We identified three classes of SNPs that were differentially prognostic or predictive of recurrence and survival in early stage NSCLC. Class 1 contained two SNPs (in MGMT) which were prognostic biomarkers for clinical outcome independent of treatment modality. Six SNPs in class 2 (MBD2, SUV39H2, MBD4, EZH1(2x), EZH2) correlated with treatment outcome for surgery alone, but not with surgery and chemotherapy, hence their effect could be reversed by chemotherapy. The last class 3 contained SNPs, which were associated with surgery and chemotherapy, but not surgery alone. For example, we observed hazard ratios for rs4751104 for recurrence of surgery and chemotherapy of 4.94 (95% CI, 1.92-12.71) and 0.89 (95% CI, 0.47- 1.67) for surgery alone. The association of most SNPs remained significant after adjusting for multiple comparisons using a q-value at 10%. By using a combination of SNPs in class 2 or 3, we were able to build genetic predictors for outcome of surgery or surgery and chemotherapy, with p < 10-6 and < 10-4, respectively. Conclusions: These results suggest that specific genetic variations in the genes mentioned above modulate clinical outcomes in patients who undergo surgery or surgery and chemotherapy for early stage NSCLC. These results may be used to build predictive models for identifying surgical patients at increased risk of adverse outcome, who may benefit from addition of chemotherapy independent of clinical stage. No significant financial relationships to disclose.

Genetic Variants in One‐carbon Metabolism‐related Genes Contribute to NSCLC Prognosis in a Chinese Population

Combined Effects of Cigarette Smoking, Gene Polymorphisms and Methylations of Tumor Suppressor Genes on Non Small Cell Lung Cancer: a Hospital-Based Case-Control Study in China

One-carbon Metabolism Pathway Gene Variants and Risk of Clear Cell Renal Cell Carcinoma in a Chinese Population.

Association of Polymorphisms in One-Carbon Metabolizing Genes and Lung Cancer Risk: a Case-Control Study in Chinese Population

Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.

Genetic Variants Of Nbs1 Predict Clinical Outcome Of Platinum-Based Chemotherapy In Advanced Non-Small Cell Lung Cancer In Chinese

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Potentially Functional Polymorphisms in Cell Cycle Genes and the Survival of Non-Small Cell Lung Cancer in a Chinese Population

The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients

Genetic Variations in Genes of Metabolic Enzymes Predict Postoperational Prognosis of Patients with Colorectal Cancer

Association of variations in platinum resistance-related genes and prognosis in lung cancer patients

Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer

Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients with Lung Cancer

Polymorphisms of Key Chemokine Genes and Survival of Non-Small Cell Lung Cancer in Chinese.

Common Genetic Variants in Cell Cycle Pathway Are Associated with Survival in Stage III-IV Non-Small-cell Lung Cancer.

Data from Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

The P38α Rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy.

Single Nucleotide Polymorphisms of One-Carbon Metabolism and Cancers of the Esophagus, Stomach, and Liver in a Chinese Population

Association of Genetic Variations in Dna-Methyltransferases, Histone-Methyltransferases, and Methylated Dna-Binding Proteins with Recurrence and Survival in Early-Stage Non-Small Cell Lung Cancer Treated with Surgery Alone or Surgery and Chemotherapy.

Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population.

Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or Ii Non-Small Cell Lung Cancer Patients